Trial Profile
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2024
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-9ER; CM 9ER
- Sponsors Bristol-Myers Squibb; Exelixis; Ono Pharmaceutical; Takeda
- 06 Feb 2024 According to an Exelixis Media Release, 4-year follow-up data from this trial presented at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.
- 27 Jan 2024 Results of a modelling analysis assessing relationship between clinical outcomes, treatment and early deterioration in HRQoL dimensions presented at the 2024 Genitourinary Cancers Symposium
- 27 Jan 2024 Results of updated efficacy (n=651) in intent-to-treat (ITT) patients and by International Metastatic RCC Database Consortium (IMDC) risk, and safety with extended 55-month follow-up of the CheckMate 9ER trial, presented at the 2024 Genitourinary Cancers Symposium.